He-He-Shu-Yang formula alleviates liver fibrosis by inhibiting hepatic stellate cell activation in vivo and in vitro
Authors:
- Fo-Lai ZengFZFo-Lai Zeng
- Mei-Jie ShiMSMei-Jie Shi
- You-Sheng MoYMYou-Sheng Mo
- Huan-Ming XiaoHXHuan-Ming Xiao
- Yu-Bao XieYXYu-Bao Xie
- Xiao-Ling ChiXCXiao-Ling Chi
Open Access
- 27 December 2025
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 17 (12)
Abstract
BACKGROUND Inhibition of liver fibrosis plays a crucial role in curbing the advancement of chronic disease to cirrhosis and even liver cancer. However, modern medicine currently lacks direct anti-fibrotic drugs. He-He-Shu-Yang formula (HHSY) is a renowned Chinese medicine for the treatment of liver fibrosis. However, its mechanism of action has not been fully unraveled. AIM To explore the efficacy and mechanism of action of HHSY through in vitro and in vivo experiments. METHODS A liver fibrosis rat model (carbon tetrachloride-induced) was treated with low- or high-dose HHSY (10.42 g/kg or 20.84 g/kg) or with colchicine (1 mg/kg) for 9 weeks. In vitro , LX-2 human hepatic stellate cells (HSCs) were activated using transforming growth factor-β1 and subsequently treated with HHSY-containing serum or a nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) inhibitor. Through high-performance liquid chromatography, histopathology (hematoxylin and eosin, Masson), immunohistochemistry, western blot, and quantitative reverse transcription polymerase chain reaction analyses, we demonstrated that HHSY inhibited HSC activation and suppressed the NOX4/reactive oxygen species (ROS)/nucleotide binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) pathway. RESULTS In vivo , HHSY improved liver function and alleviated liver pathology, including reducing inflammatory cell infiltration, and liver fibrosis in carbon tetrachloride rats. with more significant effects at higher doses. Immunohistochemistry revealed that HHSY could decrease alpha-smooth muscle actin, NOX4, and NLRP3 expression, as well as serum ROS levels (O2– and H2O2, P < 0.05). Western blot analysis confirmed HHSY also reduced NLRP3 protein levels (P < 0.05). In vitro , HHSY at 1.25% or 2.5% reduced the levels of ACTA2 mRNA, NOX4 protein and NOX4 mRNA, ROS production, and NLRP3 and IL-1β mRNA in activated LX-2 cells (P < 0.05). CONCLUSION HHSY effectively treats liver fibrosis, likely by inhibiting HSC activation through the NOX4/ROS/NLRP3 pathway. This underscores HHSY’s clinical relevance as a potential therapeutic option for liver fibrosis.Keywords
This publication has 24 references indexed in Scilit:
- Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and diseaseNature Reviews Gastroenterology & Hepatology, 2025
- Treatment of IL-18-binding protein biologics suppresses fibrotic progression in metabolic dysfunction-associated steatohepatitisCell Reports Medicine, 2025
- Naringin ameliorates liver fibrosis in zebrafish by modulating IDO1-mediated lipid metabolism and inflammatory infiltrationFood & Function, 2023
- Blueberry and cranberry extracts mitigate CCL4-induced liver damage, suppressing liver fibrosis, inflammation and oxidative stressHeliyon, 2023
- Advanced glycation end-products as mediators of the aberrant crosslinking of extracellular matrix in scarred liver tissueNature Biomedical Engineering, 2023
- Oxidative stress-mediated mitochondrial fission promotes hepatic stellate cell activation via stimulating oxidative phosphorylationCell Death & Disease, 2022
- Efficacy and safety of AnluoHuaxian pills on chronic hepatitis B with normal or minimally elevated alanine transaminase and early liver fibrosis: A randomized controlled trialJournal of Ethnopharmacology, 2022
- Hepatic stellate cells role in the course of metabolic disorders development – A molecular overviewPharmacological Research, 2021
- The Apelin–Apelin Receptor Axis Triggers Cholangiocyte Proliferation and Liver Fibrosis During Mouse Models of CholestasisHepatology, 2021
- Hepatoprotective effects of Methyl ferulic acid on alcohol-induced liver oxidative injury in mice by inhibiting the NOX4/ROS-MAPK pathwayBiochemical and Biophysical Research Communications, 2017